Steven Nissen, MD, and Luke Laffin, MD, discuss a groundbreaking phase 1 trial of a CRISPR-Cas9 gene-editing therapy targeting ANGPTL3. They explore its potential as a one-time treatment to significantly lower LDL cholesterol and triglycerides, with promising safety and efficacy data that could reshape lipid management.

Learn more about C5 Research at Cleveland Clinic.
https://my.clevelandclinic.org/research/c5research

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.